Acne characteristics in Latin American patients and the potential role of trifarotene.

BACKGROUND Individualization of treatment based on acne type and severity, location, disease burden, and patient preference is required to maximize efficacy, safety, and adherence to therapy. Latin American populations have unique attributes that must be considered as part of this process to improve clinical success and achieve patient goals. Acne is more common among patients with darker skin phototypes, in whom it is often associated with postinflammatory hyperpigmentation and scarring-the most important acne sequelae-potentially due to more frequent and more severe underlying inflammatory processes in this population. DISCUSSION These data argue for an early and proactive approach to managing acne in these patients with agents that target the inflammatory processes that underlie acne and its sequelae. As a class, retinoids offer a spectrum of activity that may be useful in addressing the unique needs of Latin American populations. CONCLUSION Trifarotene, a novel, selective retinoid, has been evaluated in relevant patient populations.

[1]  A. Alexis,et al.  Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice , 2021, American Journal of Clinical Dermatology.

[2]  B. Dréno,et al.  The Personalised Acne Care Pathway—Recommendations to guide longitudinal management from the Personalising Acne: Consensus of Experts , 2021, JAAD international.

[3]  Susan C. Taylor,et al.  The Pathogenesis and Management of Acne-Induced Post-inflammatory Hyperpigmentation , 2021, American Journal of Clinical Dermatology.

[4]  G. Webster,et al.  50 Years of Topical Retinoids for Acne: Evolution of Treatment , 2021, American Journal of Clinical Dermatology.

[5]  S. Puig,et al.  Photoprotection according to skin phototype and dermatoses: practical recommendations from an expert panel , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  B. Dréno,et al.  The Skin Microbiome: A New Actor in Inflammatory Acne , 2020, American Journal of Clinical Dermatology.

[7]  Jianyun Lu,et al.  Roles of inflammation factors in melanogenesis , 2020, Molecular medicine reports.

[8]  L. Kemény,et al.  Long‐term safety and efficacy of trifarotene 50 μg/g cream, a first‐in‐class RAR‐γ selective topical retinoid, in patients with moderate facial and truncal acne , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  M. Gooderham,et al.  Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. , 2019, Journal of the American Academy of Dermatology.

[10]  B. Dréno,et al.  Atrophic scar formation in patients with acne involves long‐acting immune responses with plasma cells and alteration of sebaceous glands , 2018, The British journal of dermatology.

[11]  B. Dréno,et al.  Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor‐γ agonist trifarotene , 2018, The British journal of dermatology.

[12]  Jerry Tan,et al.  Treating Acne in Patients With Skin of Color. , 2018, Seminars in cutaneous medicine and surgery.

[13]  E. Thoreau,et al.  Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne. , 2018, Bioorganic & medicinal chemistry letters.

[14]  H. Gollnick,et al.  Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne , 2018, Journal of the American Academy of Dermatology.

[15]  F. Penedo,et al.  Recognizing Latinos’ range of skin pigment and phototypes to enhance skin cancer prevention , 2017, Pigment cell & melanoma research.

[16]  J. Leyden,et al.  Prevalence and Risk Factors of Acne Scarring Among Patients Consulting Dermatologists in the USA , 2017, Journal of drugs in dermatology : JDD.

[17]  R. Poulton,et al.  Cumulative mental health consequences of acne: 23‐year follow‐up in a general population birth cohort study , 2016, The British journal of dermatology.

[18]  J. Leyden,et al.  Guidelines of care for the management of acne vulgaris. , 2016, Journal of the American Academy of Dermatology.

[19]  M. Kawashima,et al.  Prevalence of scars and “mini‐scars”, and their impact on quality of life in Japanese patients with acne , 2015, The Journal of dermatology.

[20]  G. Magalon,et al.  Cicatrices chéloïdes : étude d’une série de cas , 2015 .

[21]  T. S. Fröde,et al.  Melasma and assessment of the quality of life in Brazilian women* , 2015, Anais brasileiros de dermatologia.

[22]  S. Davis,et al.  The quality of life impact of acne and rosacea compared to other major medical conditions. , 2014, Journal of drugs in dermatology : JDD.

[23]  E. Bagatin,et al.  Acne vulgaris: an inflammatory disease even before the onset of clinical lesions. , 2014, Inflammation & allergy drug targets.

[24]  A. McMichael,et al.  Acne in Patients with Skin of Color: Practical Management , 2014, American Journal of Clinical Dermatology.

[25]  G. Hillebrand,et al.  Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[26]  L. Kircik Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study. , 2011, Journal of drugs in dermatology : JDD.

[27]  G. Fabbrocini,et al.  Acne Scars: Pathogenesis, Classification and Treatment , 2010, Dermatology research and practice.

[28]  Erica C Davis,et al.  Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. , 2010, The Journal of clinical and aesthetic dermatology.

[29]  W. Gulliver,et al.  Development and Validation of a Scale for Acne Scar Severity (SCAR-S) of the Face and Trunk , 2010, Journal of cutaneous medicine and surgery.

[30]  V. Callender,et al.  A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies. , 2010, The Journal of clinical and aesthetic dermatology.

[31]  J. Elder,et al.  Sun sensitivity in 5 US ethnoracial groups. , 2007, Cutis.

[32]  Mallon,et al.  The quality of life in acne: a comparison with general medical conditions using generic questionnaires , 1999, The British journal of dermatology.

[33]  W. Cunliffe,et al.  A clinical evaluation of acne scarring and its incidence , 1994, Clinical and experimental dermatology.

[34]  B. Elewski,et al.  The prevalence of acne in adults 20 years and older. , 2008, Journal of the American Academy of Dermatology.

[35]  A. Kligman,et al.  A clincohistopathological study of acne vulgaris in black females. , 1996 .